To read the full story
Related Article
- FDA Accepts Re-Submission of Izervay to Buttress Label
January 10, 2025
- FDA Turns Down Label Update for Izervay, Astellas Eyes Re-Filing
November 20, 2024
- Astellas Pulls EU Filing for Geographic Atrophy Drug
October 29, 2024
- Izervay Slows Geographic Atrophy Lesion Growth through 2 Years: Astellas
November 7, 2023
- Iveric Bio’s AMD Drug Approved in US, Launch Set for This Month: Astellas
August 8, 2023
BUSINESS
- Kowa to Launch Japan PIII for Nicox-Partnered Glaucoma Drug
May 29, 2025
- China Approves Eisai’s Insomnia Med Dayvigo
May 28, 2025
- Boehringer’s Japan Pharma Biz Grows 6 Years Running on Jardiance
May 28, 2025
- ALS Drug Radicava Now Available in Australia: Mitsubishi
May 28, 2025
- Renascience to Welcome Former MHLW Director as EVP
May 28, 2025
The traditional HR Business Partner (HRBP) model, once the gold standard for HR delivery, is undergoing a significant transformation. Many organizations, particularly in industries like pharmaceuticals, are moving towards a more agile resource model, aiming to streamline HR operations and…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…